Pioneering Therapies
for People with Neurological Diseases
We transform the lives of people suffering from chronic neurological diseases for whom oral medicines are not effective or are limited by systemic side effects.
Cerebral Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for refractory neurological diseases.
Founded by experts in the fields of neuroscience, neurosurgery and drug delivery, Cerebral Therapeutics is pioneering intracerebroventricular (ICV) therapies for people with neurological diseases. Our investigational drug therapies and companion biomarker strategies are enabled by the Company’s proprietary technology, ICVRx™.
Our Approach
We address the limitations of traditional biopharmaceutical approaches to treat neurological diseases through direct-to-brain delivery of specialized formulations of drugs, biologics and oligonucleotide therapies.
We also enable unique access to ventricular cerebrospinal fluid (CSF) which allows for CSF theranostic monitoring, biomarker guided therapy development, and personalized treatments.
Cerebral’s unique approach to targeted brain drug delivery focuses on the intracerebroventricular route of administration.
This pharmaceutical neuromodulation method:
Maximizes efficacy while greatly reducing systemic drug exposure and dose-limiting peripheral side effects
Enhances drug distribution and reduces anatomical delivery variability
Enables privileged access within the brain
Builds on decades of neurosurgical and neuromodulation experience
Permits routine ventricular CSF assessment for safety, efficacy and disease progression biomarkers while avoiding lumbar puncture
Unmet Needs for Neurological Diseases
We develop specialized pharmaceutical formulations and proprietary devices to bypass the blood brain barrier. We do this through repurposing small molecule generics and biosimilars, in-licensing products and partnering with biopharmaceutical companies, leveraging our broad ICVRx™ technology platform. Our expertise in drug delivery, pharmaceutical and medical device development enables this combination products approach. We converge expertise from the fields of neuroscience, pharmaceutics, engineering and neurosurgery to solve unmet needs in neurological diseases.
Cerebral Therapeutics’ innovations leverage 30 years of learning in the pharmaceutical, neuromodulation and neurosurgical fields by providing access to the brain’s ventricles to address unmet neurological needs.
Our initial focus is on seizure disorders, specifically refractory epilepsy.
Epilepsy affects upwards of 50 million people worldwide with approximately 1.2 million patients resistant to conventional antiseizure medications.
Cerebral’s initial clinical program uses a specialized, implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular dose of a proprietary formulation of the anti-epileptic drug valproic acid (CT-010). An optimal dose is delivered directly into the area of the brain responsible for seizure initiation and propagation.
The company reported preliminary clinical proof of concept data from a Phase 2a clinical trial demonstrating that epilepsy patients who failed multiple oral medications experienced significant and sustained reductions in seizure frequency and severity.
CNS Science Delivered
Cerebral’s team is uniquely qualified to unlock the potential of ICV biopharmaceutical therapies for neurological diseases. Our expertise uniquely intersects neuroscience, neurosurgery, targeted drug delivery, pharmaceutical and medical device development.
ICV therapy delivered via the ICVRx™ platform can be used:
For treatment in additional disease categories of:
neurodegenerative
neuroinflammatory
rare neurologic disorders
neuronopathic storage disorders
neuro-oncology
To deliver additional molecules including:
small molecules
nucleic acid therapeutics
enzyme replacement therapies
therapeutic antibodies
drug conjugates
recombinant proteins/growth factors
Join Us On Our Mission
Please contact us if you are interested in learning more about our partnerships and business opportunities to bring to the world therapies that are transformative for persons with neurological diseases.